Neuroprotective effects of pramipexole in young and aged MPTP-treated mice

Brain Research

Volumn 905, Issue 1-2, 2001, Pages 44-53

  Anderson, David W ^a   Neavin, T ^a   Smith, J A ^a   Schneider, J S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cell survival; Dopamine; MPTP; Neuroprotection; Neurorestoration; Parkinson's disease; PPX

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOROGOLD; PRAMIPEXOLE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; CATECHOLAMINE DEPLETION; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; IMMUNOCOMPETENT CELL; MALE; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NISSL SUBSTANCE; NONHUMAN; PARKINSON DISEASE; PATIENT; PRIORITY JOURNAL; STAINING; TISSUE SECTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGING; ANIMALS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CELL SURVIVAL; DOPAMINE; DOPAMINE AGENTS; FLUORESCENT DYES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NEURAL PATHWAYS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; STILBAMIDINES; SUBSTANTIA NIGRA; THIAZOLES; TYROSINE 3-MONOOXYGENASE;

EID: 0035968070     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)02466-0     Document Type: Article

References (43)

1. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
2. Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist
3. Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo
4. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
5. Pramipexole reduces reactive oxygen species production In Vivo and In Vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion
6. Pramipexole: A review of its use in the management of early and advanced Parkinson's disease
7. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
8. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats
9. 3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons
10. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles
11. Oxidative stress as a cause of Parkinson's disease
12. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice
13. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells
14. Neuroprotection by dopamine agonists
15. The etiology of Parkinson's disease with emphasis on the MPTP story
16. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures
17. 2 receptor agonist
18. 4 receptors
19. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease
20. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
21. Differences in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration: A comparison of young and older mice
22. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia
23. Oxidation reactions in Parkinson's disease
24. Attempts to obtain neuroprotection in Parkinson's disease
25. Safety and efficacy of pramipexole in early Parkinson's disease: A randomized dose-ranging study
26. Dopaminergic agonists in the treatment of Parkinson's disease: A review
27. 3-preferring agonist useful in treating Parkinson's disease
28. 3 receptor ligand, in rat striatum
29. An evaluation of cresyl echt violet as a nissl stain
30. 1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice
31. Neuroprotective effects of the dopamine agonist pramipexole and bromocriptine in 3-acetylpyridine-treated rats
32. Efficacy of pramipexole, a novel dopamine agonist as monotherapy in mild to moderate Parkinson's disease
33. Mitochondrial oxidative phosphorylation defects in Parkinson's disease
34. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
35. Mechanisms of the neurotoxicity of MPTP
36. Xenobiotic metabolism in Parkinson's disease
37. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole
38. Rescue of dying neurons: A new action for deprenyl in MPTP Parkinsonism
39. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine
40. The role of the dopamine agonists in early Parkinson's disease
41. Do dopamine agonists provide neuroprotection?
42. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydroprysidine in C57BL/6 mice